Services-Commercial Physical & Biological Research · DE · CIK 1287098
MaxCyte provides cell engineering platform technologies for cell and gene therapies and research
Comparable business profile · signals at a glance
In the 90 days to Mar 17, 2026: 1 sold $8K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Swirsky Douglas JCHIEF FINANCIAL OFFICER | Sell | 10,142 | $0.82 | $8K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.